Drug Profile
Research programme: cancer vaccines - Avidea Technologies
Latest Information Update: 09 Jan 2023
Price :
$50
*
At a glance
- Originator Avidea
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio
- 13 Dec 2021 Avidea Technologies has been acquired by Vaccitech
- 28 Dec 2020 No recent reports of development identified for research development in Cancer in Canada